

Supplementary Table 1. Summary of all hypoglycaemic episodes over the total treatment period for children participating in the extension trial.

	2–5 years of age				6–12 years of age				13–16 years of age				Total			
	N	%	E	R	N	%	E	R	N	%	E	R	N	%	E	R
All 24-h episodes	37	100	4028	55.00	59	100	7438	63.28	49	98.0	4608	46.81	145	99.3	16074	55.58
Diurnal	36	97.3	3466	47.33	59	100	6359	54.10	49	98.0	3780	38.40	144	98.6	13605	47.04
Nocturnal	34	91.9	562	7.68	56	94.9	1079	9.18	45	90.0	828	8.41	135	92.5	2469	8.54
Severe	2	5.4	2	0.03	2	3.4	2	0.02	2	4.0	3	0.03	6	4.1	7	0.02
Moderate	15	40.5	241	3.29	9	15.3	196	1.67	4	8.0	13	0.13	28	19.2	450	1.56
Mild	30	81.1	1087	14.84	59	100	5922	50.39	49	98.0	3521	35.77	138	94.5	10530	36.41
Biochemical	34	91.9	2698	36.84	50	84.7	1314	11.18	42	84.0	1068	10.85	126	86.3	5080	17.57
Unclassified	0	0	0	0	3	5.1	4	0.03	2	4.0	3	0.03	5	3.4	7	0.02

%, percentage of patients; E, number of events; N, number of patients; R, events per exposure year.

Supplementary Table 2. Adverse events over the total treatment period for children participating in the extension trial.

	2–5 years of age				6–12 years of age				13–16 years of age				Total			
	N	%	E	R	N	%	E	R	N	%	E	R	N	%	E	R
Serious adverse events	3	8.1	4	0.06	6	10.2	9	0.08	3	6.0	4	0.04	12	8.2	17	0.06
All adverse events	29	78.4	178	2.43	50	84.7	383	3.26	37	74.0	153	1.55	116	79.5	714	2.47
Severe	2	5.4	2	0.03	5	8.5	7	0.06	1	2.0	2	0.02	8	5.5	11	0.04
Moderate	11	29.7	20	0.27	21	35.6	50	0.43	9	18.0	13	0.13	41	28.1	83	0.29
Mild	29	78.4	156	2.13	47	79.7	326	2.77	34	68.0	138	1.40	110	75.3	620	2.14
Relation to IDet																
Possible	3	8.1	5	0.07	5	8.5	6	0.05	1	2.0	2	0.02	9	6.2	13	0.05
Probable	1	2.7	1	0.01	3	5.1	4	0.03	5	10.0	5	0.05	9	6.2	10	0.04
Unlikely	29	78.4	172	2.35	50	84.7	373	3.17	35	70.0	146	1.48	114	78.1	691	2.39
Relation to IAsp																
Possible	3	8.1	4	0.06	5	8.5	6	0.05	1	2.0	1	0.01	9	6.2	11	0.04
Probable	4	10.8	5	0.07	4	6.8	4	0.03	1	2.0	1	0.01	9	6.2	10	0.04

Unlikely	29	78.4	169	2.31	49	83.1	373	3.17	37	74.0	151	1.53	115	78.8	693	2.40
----------	----	------	-----	------	----	------	-----	------	----	------	-----	------	-----	------	-----	------

%, percentage of patients; E, number of events; IAsp, insulin aspart; IDet, insulin detemir; N, number of patients; R, events per exposure year